Aminocycloalkanes as DPP-IV inhibitors

A compound according to formula (I):

• wherein:
• R1 is selected from
• R2, R3, R4, R5 and R6 are each independently selected from hydrogen, lower alkyl, halogenated lower alkyl or halogen;
• provided that R2, R3, R4, R5 and R6 are not all hydrogen;
• R7 is lower alkyl;
• R8 is lower alkyl;
• X is >C═O or >SO2;
• R9 and R11 are hydrogen or together form a double bond;
• R10 and R12 are independently selected from hydrogen or lower alkyl;
• m is 1 or 2;
• n is 0, 1, or 2;
• and pharmaceutically acceptable salts thereof,
• with the further proviso that the following compounds are excluded
• 2-(m-tolyl)-cyclohexylamine, 2-(p-tolyl)-cyclohexylamine, 2-(o-tolyl)-cyclohexylamine, 2-(2-chlorophenyl)-cyclohexylamine, 2-(3-chlorophenyl)-cyclohexylamine, 2-(p-chlorophenyl)-cyclohexylamine, 2-(2-bromophenyl)-cyclohexylamine, 2-(o-tolyl)-cyclopentylamine, 2-(p-tolyl)-cyclopentylamine,
• 2-(4-chlorophenyl)-cyclopentylamine, 2-(3,5-difluorophenyl)-cyclopentylamine, 2-(3-fluorophenyl)-cyclopentylamine, 2-(4-fluorophenyl)-cyclopentylamine,
• 2-(4-bromophenyl)-cyclopentylamine, and
• 2-(4-tert-butylphenyl)-cyclopentylamine.

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of formula I

• wherein
• R1 is selected from
• R2, R3, R4, R5 and R6 are each independently selected from hydrogen, lower alkyl, halogenated lower alkyl, lower alkoxy or halogen;
• provided that R2, R3, R4, R5 and R6 are not all hydrogen;
• R7 is lower alkyl;
• R8 is lower alkyl;
• X is >C═O or >SO2;
• R9 and R11 are hydrogen or together form a double bond;
• R10 and R12 are independently selected from hydrogen or lower alkyl;
• m is 1 or 2;
• and
• n is 0, 1, or 2;
• or a pharmaceutically acceptable salt thereof;
• and a pharmaceutically acceptable carrier and/or adjuvant.